Screening for Gastric and Small Intestinal Mucosal Injury with Magnetically Controlled Capsule Endoscopy in Asymptomatic Patients Taking Enteric-Coated Aspirin

Table 1

Demographic and clinical characteristics of the patients taking enteric-coated aspirin and healthy controls.

Item	Aspirin group	Control group	value (chi-squared test or independent samples -test or Mann-Whitney test)
	Age (mean ± SD, years)	57.53 ± 9.07		55.46 ± 6.69
Male/female (n)	16/10	14/12
GSRS	3.50 (7.00)	3.0 (5.25)
Gastric Lanza score (median (IQR))	2.50 (2.15)	1.00 (1.00)
Gastric ulcer (%)	0 (0)	3 (11.5)
Gastric controlled examination time (median (IQR), min)	50.0 (6.0)	51.0 (10.0)
Small intestinal Lanza score (median (IQR))	1.00 (0.25)	0.00 (0.00)
Small intestinal ulcer	0 (0)	2 (7.7)
Small intestinal transit time (median (IQR), min)	240.0 (96.0)	238.0 (94.0)
Capsule excretion time (median (IQR), hour)	24.0 (16.0)	24.0 (10.0)

Aspirin: patients taking enteric-coated aspirin; control: healthy controls; SD: standard deviation; GSRS: Gastrointestinal Symptom Rating Scale; IQR: interquartile range.